Leukemia, Myelodysplasia, Transplantation
News
Ethnic differences in stem cell transplants may be narrowing
Major finding: Just 20% of non-white patients in the study had a fully-matched donor available, while 69% of white northern European patients did...
News
Reduced-intensity pre-transplant conditioning found easier on the brain
Vitals: Patients who had reduced-intensity conditioning before transplant had significantly better cognitive function than patients who had...
News
ASH coverage preview of the plenary session
News
CTL019 induced durable responses in children with refractory precursor B-ALL
Major finding: During 1.2-16 months of follow-up, 10 of 16 patients had an ongoing bone marrow complete response to CTL019.Data source: A phase I...
News
Oral Chinese formula rivals IV arsenic in acute promyelocytic leukemia
Major finding: Two-year disease-free survival was 98% in the RIF group vs. 95.5% in the ATO group (P < .001 for noninferiority). Data source: A...
News
Obinutuzumab approved as ‘breakthrough’ therapy for chronic lymphocytic leukemia
News
Ponatinib sales and marketing suspended
The agency placed current ponatinib trials on partial clinical hold and asked the drug’s makers, Ariad Pharmaceuticals, to end the phase 3 EPIC...
News
Sales of leukemia drug suspended because of treatment-associated vascular events
Article
BTK inhibitor ibrutinib in CLL and mantle cell lymphoma
News
Phase 3 ponatinib trial stopped due to adverse events
All trials of ponatinib were placed on partial clinical hold on October 9, after follow-up data from the phase 2 PACE trial revealed an increased...
News
Ponatinib trials put on partial hold
The US Food and Drug Administration (FDA) has paused new enrollment in the trials. Patients already enrolled will continue to receive ponatinib,...